Autonomix Medical (NASDAQ:AMIX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Autonomix Medical (NASDAQ:AMIX) from a strong sell rating to a sell rating in a research report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $42.00.

Autonomix Medical Price Performance

NASDAQ:AMIX opened at $3.54 on Friday. The firm has a 50-day moving average of $5.60 and a two-hundred day moving average of $6.78. The stock has a market cap of $3.43 million, a P/E ratio of -0.09 and a beta of -0.96. Autonomix Medical has a 1-year low of $2.44 and a 1-year high of $32.55.

Autonomix Medical (NASDAQ:AMIX) last announced its earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.38. As a group, equities analysts expect that Autonomix Medical will post -20.17 earnings per share for the current year.

About Autonomix Medical

Autonomix Medical, Inc is a medical device company developing catheter-based technologies intended to diagnose and treat conditions involving the peripheral nervous system. The company’s platform uses a miniature sensing chip integrated into a catheter to detect and measure nerve signals in targeted areas of the body.

Autonomix is initially focused on applications in pain management, including the detection and treatment of nerves associated with chronic and cancer-related pain. Its technology is designed to help physicians identify relevant nerves more precisely and guide procedures such as targeted nerve ablation or other therapeutic interventions.

The company’s development programs remain subject to clinical testing, regulatory review and authorization before any products can be broadly commercialized.